Lexeo announces positive results from their phase 1/2 clinical trial programme for FA cardiomyopathy
Lexeo Therapeutics is a pharmaceutical company developing a gene therapy called LX2006 for people with Friedreich’s ataxia (FA) hypertrophic cardiomyopathy (disease of the heart involving stretching, thickening, or stiffening of […]